KA/EN
Register
Medicines reference
Search
Search
Active substance

Sucralfate

Favourites

Mucosal protectant. Registered in Georgia: 1 human medicine. Forms: scored tablet, suspension.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Sucralfate
Dose Species Indication Route Frequency Source
500–1000 mg per animal
off-label
 Dog Gastric Ulceration By mouth every 6-8 hours
Merck GI-ulcer pharmacology
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Drugs Used to Treat Gastrointestinal Ulcers in Monogastric Animals
MSD/Merck Veterinary Manual, 2025
500–1000 mg per animal
off-label
 Dog Gastric Ulceration By mouth every 8-12 hours
Merck small-animal GI ulcers
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Gastrointestinal Ulcers in Small Animals
MSD/Merck Veterinary Manual, 2025
250–500 mg per animal
off-label
 Cat Gastric Ulceration By mouth every 8-12 hours
Merck GI-ulcer pharmacology
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Drugs Used to Treat Gastrointestinal Ulcers in Monogastric Animals
MSD/Merck Veterinary Manual, 2025
250 mg per animal
off-label
 Cat Gastric Ulceration By mouth every 8-12 hours
Merck small-animal GI ulcers
Reference book
A veterinary reference written and reviewed by specialists, summarising accepted practice. The product label gives the authorised dose.
Gastrointestinal Ulcers in Small Animals
MSD/Merck Veterinary Manual, 2025
Before use

Safety information

Known Contraindications

  • Critical (Cat)
    In a small study of cats with chronic kidney disease and normal phosphate, three of five cats given sucralfate deteriorated (vomiting, loss of appetite, constipation, worsening azotaemia). The study was stopped because of these effects and the lack of benefit, which contradicts the usual claim that sucralfate has almost no adverse effects.
    Sources: MSD Vet Manual
  • Warning
    In renal failure, aluminium absorption from sucralfate may increase. Prolonged treatment can therefore increase the risk of aluminium toxicity and requires caution.
    Sources: ACVIM · MSD Vet Manual
  • Warning
    Contraindicated in known hypersensitivity to sucralfate or any excipient. Reported hypersensitivity reactions include dyspnoea, rash, urticaria, anaphylaxis, and bronchospasm.
    Sources: FDA
  • Warning
    No pregnancy data are available in dogs or cats. Sucralfate is minimally absorbed, making systemic exposure less likely, but this is a pharmacological inference rather than evidence of safety.
    Sources: MSD Vet Manual
  • Warning
    No lactation data are available in dogs or cats. Minimal absorption makes systemic exposure less likely, but this remains a pharmacological inference rather than evidence of safety.
    Sources: Product label
  • Caution
    Sucralfate is less effective than a proton pump inhibitor for gastrointestinal ulceration and erosion, and there is no evidence that adding it to a proton pump inhibitor or an H2 blocker brings extra benefit. If a proton pump inhibitor is already given, adding sucralfate is not justified.
    Sources: ACVIM · MSD Vet Manual

Known Drug Interactions

  • Major warning Marbofloxacin + Sucralfate
    Sucralfate, antacids, and mineral supplements containing iron, aluminium, calcium, magnesium, zinc, or other divalent or trivalent cations can reduce quinolone absorption and bioavailability. The magnitude is drug-specific; marbofloxacin is covered by a direct product warning.
    Recommendation: Avoid concurrent oral administration. If both medicines are necessary, separate sucralfate or the cation-containing product from the quinolone by at least 2 hours and monitor clinical response.
    Sources: VMD SPC · VMD · FDA · ACVIM · JVIM
  • Major warning Doxycycline + Sucralfate
    In dogs, concurrent administration of sucralfate suspension reduced doxycycline AUC from 36.0 to 7.2 h·mcg/mL (relative bioavailability 20%). No interaction was detected with sucralfate tablets because tablet fragments were visible in faeces, indicating that the tablets did not disintegrate and were not effective.
    Recommendation: Separate administration by 2 hours: give doxycycline first and sucralfate 2 hours later. With this schedule, bioavailability is 74% and is not statistically different from doxycycline alone.
    Sources: JVPT
  • Minor warning Sucralfate + Levothyroxine
    Antacids containing aluminium, magnesium, or calcium, as well as ferrous sulfate and sucralfate, can reduce levothyroxine absorption.
    Recommendation: Separate levothyroxine from antacids, iron, or sucralfate by at least 2 hours.
  • Minor warning Enrofloxacin + Sucralfate
    The concomitant administration of substances containing magnesium or aluminium may reduce the absorption of enrofloxacin. These drugs should be administered two hours apart.
    Recommendation: Separation is not critical in dogs, but a 2-hour interval is safe and label-consistent. No comparable measurement exists in cats; use a 2-hour interval in cats.
    Sources: VMD SPC · VMD · JVIM
  • Minor warning Oxytetracycline + Sucralfate
    Divalent and trivalent cations, including magnesium, iron, aluminium, and calcium, can chelate oxytetracycline and reduce its absorption. Do not give it at the same time as milk or antacids.
    Recommendation: Separate this medicine from oral oxytetracycline in time.
Latin name
Sucralfate
Georgian name
სუკრალფატი
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
1 of 2 forms
Products
Sucralan, Venter
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration2

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Sucralan 1 g/5 ml, Suspension

oral suspension, sachet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate has a defined mucosal-protective role
5.9/10
Weak evidence support
vetman assessment

Sucralan

1 g/5 ml, oral suspension, sachet, human medicine
Assessed clinical scopeDog · Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate has a defined mucosal-protective role · By mouth
Care settingVeterinarian-directed outpatient or inpatient adjunct after diagnosis, cause-directed treatment and an interaction-aware administration schedule
vetman score 5.9/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-036586 · Verified on 16 Oct 2026 Off-label use

A more usable sucralfate presentation than an intact tablet, but still a selectively justified, weakly evidenced adjunct. PPI superiority, frequent separated dosing, interactions and renal aluminium risk constrain value.

Regulatory and scientific credibility7.0/10

The exact current BASG leaflet, Austrian authorisation and active Georgian registration make composition and presentation transparent. Veterinary authorisation and exact-product dog/cat outcomes are absent, so credibility is good rather than high.

Clinical efficacy4.0/10

A plausible local mucosal-barrier effect and professional dosing guidance exist, but canine clinical-outcome evidence is limited, PPIs are superior and routine addition to adequate acid suppression is unsupported.

Safety and tolerability6.0/10

Minimal systemic absorption is favourable, but constipation, bezoar risk, 175 mg aluminium per sachet, renal accumulation and clinically important absorption interactions remain.

Clinical practicality7.0/10

The ready 200 mg/ml suspension avoids unreliable intact-tablet disintegration, and one 5 ml sachet supplies a 1 g upper dog unit. A 500 mg dose needs an accurately measured half-sachet; frequent separated dosing and unknown opened-sachet stability remain burdens.

Full-course cost-effectiveness-

Price not assessed: no current Georgian clinic acquisition price and no diagnosis-specific full-course comparator dataset were verified.

Important safety and use flags

  • Use only for a selected confirmed or strongly suspected upper-GI ulcerative/erosive lesion when sucralfate has a defined role. PPIs are generally superior and routine add-on benefit is unsupported.
  • This is extra-label use of a human product in dogs and cats. Document the indication, veterinary dose source, interaction schedule and response endpoint; do not transfer the human Sucralan regimen.
  • Use the 200 mg/ml concentration only to convert a selected veterinary regimen. Preserve the published frequency and feline-upper-dose alternatives; do not merge them into one universal schedule.
  • Knead the sachet before measuring. Fractions require an appropriate oral syringe; the full sachet is the only validated unit, and stability, homogeneity and hygiene of a stored opened remainder are unverified.
  • Separate from food and interacting oral medicines according to the co-administered drug and veterinary protocol. Binding can reduce tetracycline, fluoroquinolone, levothyroxine, digoxin, phenytoin, theophylline, azole and other critical oral exposure.
  • Interaction magnitude is drug-specific: canine studies show marked doxycycline and ciprofloxacin effects, while enrofloxacin was not materially changed. Follow the exact co-medication evidence rather than a class-wide interval guess.
  • Avoid severe renal impairment and strongly reconsider feline CKD use. Each 5 ml contains aluminium equivalent to 175 mg; three of five CKD cats decompensated at 500 mg q8h in a small direct study.
  • Monitor vomiting, anorexia, constipation, hydration, azotaemia and response. Delayed gastric emptying, impaired motility, enteral feeding or aspiration risk increase bezoar and administration hazards.
  • Each 5 ml also contains 2 g of 70% sorbitol solution plus methyl/propyl parabens and caramel flavour. Consider GI tolerance and hypersensitivity; veterinary flavour acceptance and complete flavour composition are unverified.
  • Pregnancy and lactation safety are not established in dogs or cats. The human leaflet short-use advice and minimal-absorption rationale do not prove target-animal reproductive safety.
Assessment sources
  1. Sucralan BASG leaflet2025
  2. Sucralan product page2026
  3. Carafate suspension FDA2022
  4. MHRA sucralfate endpoint2026
  5. Merck GI-ulcer pharmacology2025
  6. Merck small-animal GI ulcers2025
  7. ACVIM GI-protectant consensus2018
  8. Canine fluoroquinolone interaction2016
  9. Canine tablet-dispersion study2015
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate has a defined mucosal-protective role
5.2/10
Weak evidence support
vetman assessment

Sucralan

1 g/5 ml, oral suspension, sachet, human medicine
Assessed clinical scopeCat · Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate has a defined mucosal-protective role · By mouth
Care settingVeterinarian-directed outpatient or inpatient adjunct after diagnosis, cause-directed treatment and an interaction-aware administration schedule
vetman score 5.2/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-036586 · Verified on 16 Oct 2026 Off-label use

A doseable suspension with weak feline outcome support and a direct CKD safety signal. Use only when a defined mucosal-protective role outweighs the interaction, renal and administration burdens.

Regulatory and scientific credibility7.0/10

The exact current BASG leaflet, Austrian authorisation and active Georgian registration make composition and presentation transparent. Veterinary authorisation and exact-product dog/cat outcomes are absent, so credibility is good rather than high.

Clinical efficacy3.5/10

The same plausible local mechanism applies, but feline clinical-outcome evidence is even thinner; PPIs are superior and routine addition to adequate acid suppression is unsupported.

Safety and tolerability4.5/10

Minimal systemic absorption is favourable, but three of five CKD cats decompensated at a referenced upper regimen; constipation, aluminium accumulation and major absorption interactions further narrow safety.

Clinical practicality6.0/10

The suspension is preferable to an intact tablet, but common 1.25–2.5 ml feline amounts require accurate fractions from a 5 ml sachet. Repeated separated dosing, restraint, waste and unknown opened-sachet stability limit practicality.

Full-course cost-effectiveness-

Price not assessed: no current Georgian clinic acquisition price and no diagnosis-specific full-course comparator dataset were verified.

Important safety and use flags

  • Use only for a selected confirmed or strongly suspected upper-GI ulcerative/erosive lesion when sucralfate has a defined role. PPIs are generally superior and routine add-on benefit is unsupported.
  • This is extra-label use of a human product in dogs and cats. Document the indication, veterinary dose source, interaction schedule and response endpoint; do not transfer the human Sucralan regimen.
  • Use the 200 mg/ml concentration only to convert a selected veterinary regimen. Preserve the published frequency and feline-upper-dose alternatives; do not merge them into one universal schedule.
  • Knead the sachet before measuring. Fractions require an appropriate oral syringe; the full sachet is the only validated unit, and stability, homogeneity and hygiene of a stored opened remainder are unverified.
  • Separate from food and interacting oral medicines according to the co-administered drug and veterinary protocol. Binding can reduce tetracycline, fluoroquinolone, levothyroxine, digoxin, phenytoin, theophylline, azole and other critical oral exposure.
  • Interaction magnitude is drug-specific: canine studies show marked doxycycline and ciprofloxacin effects, while enrofloxacin was not materially changed. Follow the exact co-medication evidence rather than a class-wide interval guess.
  • Avoid severe renal impairment and strongly reconsider feline CKD use. Each 5 ml contains aluminium equivalent to 175 mg; three of five CKD cats decompensated at 500 mg q8h in a small direct study.
  • Monitor vomiting, anorexia, constipation, hydration, azotaemia and response. Delayed gastric emptying, impaired motility, enteral feeding or aspiration risk increase bezoar and administration hazards.
  • Each 5 ml also contains 2 g of 70% sorbitol solution plus methyl/propyl parabens and caramel flavour. Consider GI tolerance and hypersensitivity; veterinary flavour acceptance and complete flavour composition are unverified.
  • Pregnancy and lactation safety are not established in dogs or cats. The human leaflet short-use advice and minimal-absorption rationale do not prove target-animal reproductive safety.
Assessment sources
  1. Sucralan BASG leaflet2025
  2. Sucralan product page2026
  3. Carafate suspension FDA2022
  4. MHRA sucralfate endpoint2026
  5. Merck GI-ulcer pharmacology2025
  6. Merck small-animal GI ulcers2025
  7. ACVIM GI-protectant consensus2018
  8. Feline CKD sucralfate study2016
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sucralfate200 mg/ml
Formulation Type
Suspension
Administration route
By mouth
Manufacturer
G.L. Pharma GmbH · Austria
Registration
Georgia Yes, human
In force until 07 Oct 2027
Human (Ministry of Health, RAMA)
In the register: სუკრალანი 1 გ/5 მლ, ორალური სუსპენზია პაკეტში
№ რ-036586
Verified on: 16 Oct 2026
 EU Yes, human
№ 1-20564
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Use a veterinarian-selected sucralfate regimen, not the human Sucralan schedule. Existing veterinary references preserve separate alternatives: dogs 500–1000 mg (2.5–5 ml) PO q6–8h or q8–12h; cats 250–500 mg (1.25–2.5 ml) PO q8–12h, with a separate 250 mg (1.25 ml) alternative and a safety signal at 500 mg q8h in feline CKD. Knead the sachet before measuring. One sachet contains 5 ml; any fraction needs an appropriate oral syringe. Opened-partial-sachet stability and homogeneity are unverified, so do not assume the remainder can be stored.

Venter 1 g tablet, Scored tablet

human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate is specifically justified
5.0/10
Weak evidence support
vetman assessment

Venter

1 g tablet, human medicine
Assessed clinical scopeDog · Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate is specifically justified · By mouth
Care settingVeterinarian-directed outpatient or inpatient adjunct after defining the lesion, primary cause, concurrent treatment and interaction schedule
vetman score 5.0/10 Weak evidence support
Evidence confidence: Medium Georgia: No longer listed · № რ-023029 · Verified on 22 Oct 2026 Off-label use

A selectively useful but weakly evidenced human-product adjunct. Exact-product transparency is acceptable, while limited outcome evidence, PPI superiority, interactions and unreliable intact-tablet performance constrain value.

Regulatory and scientific credibility5.5/10

Exact current Slovenian human product information and status are transparent, but Georgia is expired, veterinary authorisation is absent and exact-product veterinary outcome evidence is limited.

Clinical efficacy4.0/10

A plausible mucosal barrier effect and professional dosing guidance exist, but animal outcome evidence is limited, PPIs are superior and routine addition to adequate acid suppression is unsupported.

Safety and tolerability6.0/10

Low systemic absorption is favourable, but constipation, bezoar risk, aluminium accumulation in renal dysfunction and clinically important absorption interactions remain.

Clinical practicality4.0/10

Frequent fasting/separated dosing and unreliable intact-tablet disintegration are burdensome. Water dispersion is possible, but the score line does not validate an accurate 500 mg fraction.

Full-course cost-effectiveness-

Current exact-product Georgian price and availability were not verified; cost is excluded.

Important safety and use flags

  • Use only for a selected confirmed or strongly suspected upper-GI ulcerative/erosive lesion when sucralfate has a defined role. PPIs are generally superior and routine add-on benefit is unsupported.
  • Do not administer the tablet intact when reliable local activity is required. Disperse it in water according to the exact product information or select a suitable suspension.
  • The score line does not establish equal-dose halves or quarters. Do not invent 500 mg or 250 mg accuracy from visual subdivision of this 1 g tablet.
  • Give apart from food and interacting oral medicines by the interval applicable to the other medicine and clinical protocol; adsorption/chelation can cause treatment failure.
  • Interaction magnitude is drug-specific. Direct evidence supports marked doxycycline and ciprofloxacin effects, while enrofloxacin was not materially changed; marbofloxacin carries its own label warning.
  • Avoid or strictly limit in renal dysfunction because aluminium may accumulate. In a small feline CKD study, three of five treated cats clinically decompensated.
  • Monitor vomiting, anorexia, constipation, hydration, azotaemia and bezoar or impaired-motility risk; reassess promptly if the patient worsens.
  • Pregnancy and lactation safety data are insufficient in dogs and cats. Minimal absorption is a pharmacological inference, not proof of reproductive safety.
  • The exact Georgian Venter 1000 mg registration expired in 2022. Another sucralfate brand, concentration or formulation does not transfer market status to this tablet.
  • This is extra-label cascade use of a human medicine in dogs and cats. Document the reason, exact preparation method, dose source, interaction schedule and response endpoint.
Assessment sources
  1. Venter Slovenia record2026
  2. Venter Slovenia PIL2013
  3. Venter Georgia audit2026
  4. ACVIM GI-protectant consensus2018
  5. Merck GI-ulcer pharmacology2025
  6. Merck small-animal GI ulcers2025
  7. Canine tablet-dispersion study2015
  8. Feline CKD sucralfate study2016
  9. Canine fluoroquinolone interaction2016
  10. Carafate FDA label2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate is specifically justified
4.2/10
Weak evidence support
vetman assessment

Venter

1 g tablet, human medicine
Assessed clinical scopeCat · Selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate is specifically justified · By mouth
Care settingVeterinarian-directed outpatient or inpatient adjunct after defining the lesion, primary cause, concurrent treatment and interaction schedule
vetman score 4.2/10 Weak evidence support
Evidence confidence: Medium Georgia: No longer listed · № რ-023029 · Verified on 22 Oct 2026 Off-label use

A weakly evidenced human-product adjunct with a poor feline dose-form fit and a direct CKD safety signal. Use only when its specific mucosal role clearly justifies those limitations.

Regulatory and scientific credibility5.5/10

Exact current Slovenian human product information and status are transparent, but Georgia is expired, veterinary authorisation is absent and exact-product veterinary outcome evidence is limited.

Clinical efficacy3.5/10

The same mechanistic rationale applies, but feline clinical-outcome evidence is even thinner; PPIs are superior and routine addition to adequate acid suppression is unsupported.

Safety and tolerability4.5/10

Low systemic absorption is favourable, but direct feline data found vomiting and decompensation in three of five CKD cats at a referenced upper regimen, alongside constipation and aluminium concerns.

Clinical practicality2.5/10

Frequent separated dosing, unreliable intact-tablet disintegration and an unvalidated fractional 1 g unit are particularly poorly matched to cats; water dispersion does not make visual quarters dose-accurate.

Full-course cost-effectiveness-

Current exact-product Georgian price and availability were not verified; cost is excluded.

Important safety and use flags

  • Use only for a selected confirmed or strongly suspected upper-GI ulcerative/erosive lesion when sucralfate has a defined role. PPIs are generally superior and routine add-on benefit is unsupported.
  • Do not administer the tablet intact when reliable local activity is required. Disperse it in water according to the exact product information or select a suitable suspension.
  • The score line does not establish equal-dose halves or quarters. Do not invent 500 mg or 250 mg accuracy from visual subdivision of this 1 g tablet.
  • Give apart from food and interacting oral medicines by the interval applicable to the other medicine and clinical protocol; adsorption/chelation can cause treatment failure.
  • Interaction magnitude is drug-specific. Direct evidence supports marked doxycycline and ciprofloxacin effects, while enrofloxacin was not materially changed; marbofloxacin carries its own label warning.
  • Avoid or strictly limit in renal dysfunction because aluminium may accumulate. In a small feline CKD study, three of five treated cats clinically decompensated.
  • Monitor vomiting, anorexia, constipation, hydration, azotaemia and bezoar or impaired-motility risk; reassess promptly if the patient worsens.
  • Pregnancy and lactation safety data are insufficient in dogs and cats. Minimal absorption is a pharmacological inference, not proof of reproductive safety.
  • The exact Georgian Venter 1000 mg registration expired in 2022. Another sucralfate brand, concentration or formulation does not transfer market status to this tablet.
  • This is extra-label cascade use of a human medicine in dogs and cats. Document the reason, exact preparation method, dose source, interaction schedule and response endpoint.
Assessment sources
  1. Venter Slovenia record2026
  2. Venter Slovenia PIL2013
  3. Venter Georgia audit2026
  4. ACVIM GI-protectant consensus2018
  5. Merck GI-ulcer pharmacology2025
  6. Merck small-animal GI ulcers2025
  7. Canine tablet-dispersion study2015
  8. Feline CKD sucralfate study2016
  9. Canine fluoroquinolone interaction2016
  10. Carafate FDA label2024
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Sucralfate1000 mg
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
KRKA, d.d., Novo mesto · Slovenia
Registration
Georgia No longer listed
Was registered; not in the current register
Human (Ministry of Health, RAMA)
In the register: ვენტერი 1000 მგ
№ რ-023029
Verified on: 22 Oct 2026
 EU Yes, human
№ 5363-I-2084/09
Verified on: 22 Oct 2026
 UK Not confirmed
Unresolved exact-product endpoint
Verified on: 22 Oct 2026
 US Not confirmed
Unresolved exact-product endpoint
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Veterinarian-directed extra-label use only for selected confirmed or strongly suspected upper-GI ulcerative/erosive disease when sucralfate is specifically justified. Do not give the tablet intact when reliable local activity is required: disperse it in water according to the exact product information or use a suitable suspension. The score line does not validate equal halves or quarters, so do not calculate an unverified fractional tablet dose.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗